Small molecule · developed by Merck &
MK-6916 is an oral tablet given at 120 mg or 70 mg every 12 hours.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07862595 | Phase 2 | Pain Management | Recruiting | MRK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pain Management
Updated Nov 8, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →